Trial Profile
A Clinical Trial to Evaluate the Impact of Broadly Neutralizing Antibodies VRC01LS and 10-1074 on Maintenance of HIV Suppression in a Cohort of Early-Treated Children in Botswana (Dual bNAb Treatment in Children)
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 19 Apr 2023
Price :
$35
*
At a glance
- Drugs VRC 01LS (Primary) ; Zinlirvimab (Primary) ; Antiretrovirals
- Indications HIV infections
- Focus Adverse reactions; Proof of concept; Therapeutic Use
- 22 Feb 2023 Results presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
- 15 Sep 2022 Results evaluating the safety and pharmacokinetics of dual intravenous VRC01LS and 10-1074 in very early-treated children with HIV-1, published in the JAIDS
- 14 Jul 2022 Status changed from active, no longer recruiting to completed.